Trivitron Healthcare- India’s Largest MNC in Medical Technology Appoints WMA as their PR Agency...
Lipitor to generate about $700 million for Ranbaxy in the U.S.
WHO questions integrity of clinical trials data of Quest Life Sciences
Health tops new Nestle MD’s agenda
ClearPath introduces 3D Aligners for the first time in India
GlaxoSmithKline Pharmaceuticals Net Sales up 16 percent
PAT before Exceptional Items Grows 7.4% in Fourth Quarter of FY 2012
Mumbai, Maharashtra, India, Tuesday, February 19, 2013 -- (Business Wire India) -- GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the fourth quarter ended 31st December, 2012. The growth in Net Sales was 16% and Profit After Tax and before Exceptional Items was 7.4%. The core Pharmaceuticals business grew by 15.9% for the quarter.
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
T.CON and Perlen Packaging achieve a successful global SAP S/4HANA conversion
Columbia Asia Hospital, Patiala organizes Around 1200 students from various schools, colleges take part...
Watson Confirms Velcade® Patent Challenge
Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis, Inc., which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market bortezomib.
Actavis' ANDA product is a generic version of Millennium Pharmaceuticals' Velcade ® (bortezomib), which is a proteasome inhibitor, for intravenous or subcutaneous administration, approved for the treatment of patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior therapy.